Jason Thonhoff News Today

This investigator-initiated, double-blind, placebo-controlled study evaluates the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with...

Serum 4-Hydroxynonenal levels are significantly increased in ALS patients- the higher the 4-HNE level, the faster the progression and shorter the survival; Serum 4-HNE levels are increased in...

4-Hydroxynonenal levels strongly correlate with rate of Amyotrophic Lateral Sclerosis disease progression and survival of patients from onset and diagnosis to death 4-HNE levels may serve as a...

Coya’s Scientific Board Chairman Dr. Stanley Appel and Chief Medical Officer Dr. Fred Grossman to participate in discussion hosted by BTIG Analyst Tom Shrader ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Alireza Faridar, the Stanley H. Appel Chair in Translational...

Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseases Expansion of COYA 302 into...

License from University of Nebraska Medical Center covers multiple low dose interleukin-2 combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor ; New data, viewable...

License from University of Nebraska Medical Center covers multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF);New data, viewable here, illustrate that the combination of ld IL-2 + GM-CSF results in a 4-6 fold synergistic increase in Tr...

Dr. Appel to discuss the potential of combination immunotherapy in ALS ...

All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dysfunctional regulatory T cell biology which may limit efficacy of...